The ZFP91 antibody targets the ZFP91 protein, a zinc finger protein encoded by the ZFP91 gene in humans. Zinc finger proteins are characterized by conserved structural motifs that facilitate DNA or RNA binding, often playing roles in transcriptional regulation, ubiquitination, or signal transduction. ZFP91. also identified as a non-canonical E3 ubiquitin ligase, has been implicated in modulating critical cellular processes, including NF-κB and MAPK signaling pathways, apoptosis, and immune responses. It interacts with substrates like Roquin-1 and NEMO, influencing protein stability and downstream signaling events. Dysregulation of ZFP91 is linked to diseases such as cancer, autoimmune disorders, and viral infections. For instance, it promotes tumorigenesis in certain cancers by enhancing cell proliferation or inhibiting apoptosis. Antibodies against ZFP91 are essential tools for studying its expression, localization, and molecular interactions via techniques like Western blotting, immunoprecipitation, and immunofluorescence. Recent research highlights its potential as a therapeutic target, particularly in oncology and inflammation-related pathologies. However, its precise mechanisms remain under investigation, necessitating further functional studies to elucidate its role in health and disease.